These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36062490)

  • 21. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).
    Karthic A; Kesarwani V; Singh RK; Yadav PK; Chaturvedi N; Chauhan P; Yadav BS; Kushwaha SK
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35164069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.
    Kulkarni P; Padmanabhan S
    Biotechnol Lett; 2022 Jul; 44(7):831-843. PubMed ID: 35608787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Favipiravir and COVID-19: A Simplified Summary.
    Ghasemnejad-Berenji M; Pashapour S
    Drug Res (Stuttg); 2021 Mar; 71(3):166-170. PubMed ID: 33176367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity.
    Tsuji M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluorescence of ocular surface in a Covid -19 patient after Favipiravir treatment: a case report.
    Doran MA; Aytogan H; Ayıntap E
    Virol J; 2021 Jul; 18(1):146. PubMed ID: 34256791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
    Udwadia ZF; Singh P; Barkate H; Patil S; Rangwala S; Pendse A; Kadam J; Wu W; Caracta CF; Tandon M
    Int J Infect Dis; 2021 Feb; 103():62-71. PubMed ID: 33212256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioequivalence study of two favipiravir tablet formulations in healthy male subjects.
    Sağlam O; Güney B; Saraner N; Sevici G; Doğan-Kurtoğlu E; Ulusoy MG; Demiray G; Nacak M; Erenmemişoğlu A; Ozbek M; Aytaç P
    Int J Clin Pharmacol Ther; 2021 May; 59(5):409-416. PubMed ID: 33624584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Favipiravir-induced fever in coronavirus disease 2019: A report of two cases.
    Takoi H; Togashi Y; Fujimori D; Kaizuka H; Otsuki S; Wada T; Takeuchi Y; Abe S
    Int J Infect Dis; 2020 Dec; 101():188-190. PubMed ID: 32992014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir.
    Hanai Y; Yoshizawa S; Matsuo K; Uekusa S; Miyazaki T; Nishimura K; Mabuchi T; Ohashi H; Ishii Y; Tateda K; Yoshio T; Nishizawa K
    Diagn Microbiol Infect Dis; 2022 Apr; 102(4):115640. PubMed ID: 35193798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Hanna CR; Blyth KG; Burley G; Carmichael S; Evans C; Hinsley S; Khadra I; Khoo S; Lewsley LA; Jones RR; Sharma R; Taladriz-Sender A; Thomson EC; Scott JT
    Trials; 2020 Nov; 21(1):935. PubMed ID: 33213530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.
    Nasir M; Perveen RA; Saha SK; Talha KA; Selina F; Islam MA
    Mymensingh Med J; 2020 Jul; 29(3):747-754. PubMed ID: 32844821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
    Khamis F; Al Naabi H; Al Lawati A; Ambusaidi Z; Al Sharji M; Al Barwani U; Pandak N; Al Balushi Z; Al Bahrani M; Al Salmi I; Al-Zakwani I
    Int J Infect Dis; 2021 Jan; 102():538-543. PubMed ID: 33181328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.
    Pertinez H; Rajoli RKR; Khoo SH; Owen A
    J Antimicrob Chemother; 2021 Jul; 76(8):2121-2128. PubMed ID: 34075418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
    Dabbous HM; Abd-Elsalam S; El-Sayed MH; Sherief AF; Ebeid FFS; El Ghafar MSA; Soliman S; Elbahnasawy M; Badawi R; Tageldin MA
    Arch Virol; 2021 Mar; 166(3):949-954. PubMed ID: 33492523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase.
    Abdelnabi R; Morais ATS; Leyssen P; Imbert I; Beaucourt S; Blanc H; Froeyen M; Vignuzzi M; Canard B; Neyts J; Delang L
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28381577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient.
    Tawara J; Uehara T; Sakao S; Igari H; Taniguchi T; Kasai H; Takayanagi S; Yahaba M; Shimada R; Ikusaka M
    Intern Med; 2021 Apr; 60(7):1115-1117. PubMed ID: 33583886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach.
    Abdel-Halim H; Hajar M; Hasouneh L; Abdelmalek SMA
    Drug Des Devel Ther; 2022; 16():2995-3013. PubMed ID: 36110398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models.
    Wang Y; Li P; Rajpoot S; Saqib U; Yu P; Li Y; Li Y; Ma Z; Baig MS; Pan Q
    Sci Rep; 2021 Dec; 11(1):23465. PubMed ID: 34873274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia.
    Mutair AA; Shamou J; Alhumaid S; Layqah L; Ahmed GY; Thoyaja K; Mohaini MA; Almahmoud S; Barry M; Khan A; Dhama K; Al-Jamea LH; Woodman A; Rabaan AA
    J Infect Public Health; 2022 Apr; 15(4):389-394. PubMed ID: 35299062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights.
    Parlak C; Alver Ö; Ouma CNM; Rhyman L; Ramasami P
    Drug Res (Stuttg); 2022 Jan; 72(1):34-40. PubMed ID: 34535038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.